iCAD, Inc. (ICAD)

Market Cap	40.72M
Revenue (ttm)	18.94M
Net Income (ttm)	-2.71M
Shares Out	26.35M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	365,136
Open	1.540
Previous Close	1.560
Day's Range	1.480 - 1.573
52-Week Range	1.180 - 2.650
Beta	1.47
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About ICAD

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 3, 1986
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: ICAD
• Website: https://www.icadmed.com

Financial Performance

In 2023, iCAD, Inc.'s revenue was $17.32 million, a decrease of -12.54% compared to the previous year's $19.80 million. Losses were -$4.85 million, -64.51% less than in 2022.